Download
← All fact checksMorning run · October 31, 2026 · #5 by reach
HealthConflictEconomyEvent claim

Did the Pentagon award $41 million to iX Biopharma for a ketamine wafer?

Did the Pentagon award a roughly $41 million contract to Singapore's iX Biopharma to develop 'ketamine wafers' for the US military?

True

Every checkable claim matches the February 2026 contract, HHS declaration and company filings.

TRUE. In February 2026 the Pentagon awarded a US$40.95 million contract to Singapore-based iX Biopharma to develop Wafermine, a sublingual ketamine wafer for acute pain. The clip accurately describes the award, the company's push for FDA Emergency Use Authorization for troops, and its caveats. Every checkable detail matches official filings and reporting.

+4Sources ↓Original post ↗
Genuine
The post as it circulated, labelled by our media check.Video · 1:28

Claims

✓ 6 true

The Pentagon (Defense Department) awarded nearly $41 million to Singapore-based iX Biopharma to develop a small ketamine-packed wafer.1236

✓ TrueCentral claimHigh confidence

This is the claim the whole clip rests on, and it holds. iX Biopharma's own Singapore Exchange announcement, dated 12 February 2026, states that it was awarded a US$40.95 million development contract by the United States Government for Wafermine. Politico Pro describes a $41 million non-competitive contract awarded in February to the same company, and the Military Times/Navy Times explainer repeats the figure. The three sources are genuinely independent of each other: one is the company's regulatory filing, one is trade-press reporting from the Pentagon's own media ecosystem, and one is a separate POLITICO investigation. The $40.95 million in the filing rounds to the 'nearly $41 million' used in the clip. A reader should weigh that this is a sole-source, or Other Transaction Agreement, award rather than a competitive tender, but that does not change the amount or recipient. Nothing in the record supports a different company, a different amount or a different year.

Wafermine is a sublingual ketamine wafer designed to treat moderate-to-severe acute pain without requiring an injection, absorbed through tissue under the tongue.125

✓ TrueHigh confidence

This description of the product matches the company's own regulatory description and independent health reporting. iX Biopharma's filing describes Wafermine as a patented sublingual racemic ketamine wafer that dissolves under the tongue, letting ketamine pass through the oral mucosa into the bloodstream. MedPage Today and the Military Times/Navy Times reporting repeat the same route of delivery and the same pain indication. The clip's explanation — that this avoids an injection when seconds matter — is consistent with those descriptions. The key point for a reader is that the source for the product's basic design is the manufacturer, but the description is also repeated by independent outlets with no stake in the company's share price, so it is not a single-source claim. The phrase 'world's first patented' comes from the company and should be read as a corporate claim, not an independently verified record.

The company is seeking FDA Emergency Use Authorization so troops could potentially use the drug before it receives full FDA approval.47

✓ TrueHigh confidence

The contract is explicitly structured to support an Emergency Use Authorization. RTTNews, reporting the award via Nasdaq, states that the 36-month programme is designed to support an EUA 'allowing Department of Defense use prior to full approval.' Politico's October 2026 investigation adds that iX Biopharma extended its EUA timeline and now projects filing with the FDA 'in the next 12 months.' So the company is pursuing an EUA, but it has not filed yet and the product is not authorised. The clip states this accurately: it says the company is 'trying to get emergency authorization' and that medics are not 'getting boxes of ketamine wafers tomorrow.' A reader should note the difference between seeking an authorisation and holding one; the clip uses the correct language and does not overstate the stage.

The push for emergency authorization follows a federal declaration that circumstances exist justifying use of certain unapproved medications for troops facing severe battlefield injuries.25

✓ TrueHigh confidence

The sequence of declarations in the clip is accurate. MedPage Today reports that in July 2026 Defense Secretary Pete Hegseth determined a military emergency existed, and the following month HHS Secretary Robert F. Kennedy Jr. determined that circumstances existed to justify emergency use of certain drugs. Military Times/Navy Times specifies the HHS declaration date as 3 September 2026 and describes it as opening the possibility of early official authorisation. The clip does not name the officials, but it correctly describes a federal declaration for unapproved medications for troops with severe injuries. The two outlets are independent and both report the same two-step process. A minor gap is that the clip simplifies the legal basis; the declaration is specific to certain drugs identified by the Pentagon for moderate-to-severe acute pain in casualties, not a blanket authorisation.

Ketamine has become increasingly common in military trauma care, especially for seriously wounded patients, as a non-opioid alternative.23

✓ TrueHigh confidence

This context statement is supported by the reporting the clip draws on. Military Times/Navy Times and POLITICO Pro both describe ketamine as an increasingly common battlefield analgesic in military trauma care, and the Navy Times piece cites a 2023 study describing ketamine as a first-line battlefield analgesic since 2012, with use rising as opioid use for battlefield injuries declined. Ketamine is not an opioid and causes less respiratory depression than morphine or fentanyl. The clip's framing — that this is a non-opioid option — matches that reporting. One caution: the statement is a general trend claim, not a specific number, so it is supported by expert and press consensus rather than a single dataset. That is enough for a TRUE rating here because the trend is widely described by independent outlets.

There are questions surrounding one of the company's U.S. manufacturing partners, and the drug is still going through the authorization process.34

✓ TrueHigh confidence

This is the clip's own caveat, and it is independently confirmed. Politico's October 2026 investigation found that iX Biopharma's U.S. manufacturing partner, Orion Specialty Labs in Henderson, Nevada, had not obtained the required Nevada Board of Pharmacy licence. The same article reports that iX Biopharma extended its EUA timeline and now expects to file with the FDA in the next 12 months. Because the clip is the thing being checked, it is notable that its caveats are the part most likely to be omitted by a less careful outlet. The Politico investigation is independent of the company and of the Military Times newsroom, and it goes beyond the video rather than repeating it. A reader should weigh that the licence issue concerns a manufacturing partner, not the ketamine wafer itself, and that the clip does not name the partner or the state.

What was posted

Facebook

A Facebook reel from a Military Times/Defense News vertical video presents a studio explainer by presenter Christopher Chaos. The clip reports that the Pentagon wants ketamine on the battlefield in a small wafer form that dissolves under the tongue, and that the Defense Department awarded nearly $41 million to develop Wafermine. It also says the company is seeking emergency authorization and notes that the product is still in the pipeline and that questions surround a U.S. manufacturing partner. It ends by asking viewers for their thoughts.

“The Pentagon awarded a multi-million-dollar contract to the Singapore-based iX Biopharma to develop a small, ketamine-packed wafer.”

The reel is a repost of a branded Military Times/Defense News vertical explainer tied to a 22 October 2026 article. The Facebook post title adds the outlet name 'Defense News'.

The media

Video
GenuinePresented as real footage

✓ What is genuine

The presenter is a known Military Times video journalist, and the video is a branded news explainer tied to a 22 October 2026 Military Times article. The underlying contract, product and regulatory steps it describes are documented in official filings and independent reporting.

The tells

  • ●●● Strong signal The presenter appears consistent across keyframes: facial features, lip-sync, hands and clothing are stable, with no morphing or impossible anatomy.our visual review
  • ●●○ Supporting signal The set — a flag backdrop and studio lighting — is coherent throughout, with no garbled signage or shifting text overlays.our visual review
  • ●●○ Supporting signal The cutaway footage of a robotic pharmaceutical line filling blister packs and of a combat medic handling a syringe is ordinary illustrative stock, not a claim of secret footage.our visual review

Synthetic-media detector

Detector not consulted

Sources settled the claim on their own; the detector was not needed.

How we checked the media

  • We reviewed keyframes from the video by eye for consistency of the presenter, set, text overlays and hands.
  • We compared the video's claims with the company's own regulatory filings and independent reporting.
  • We did not run an automated synthetic-media detector; our assessment rests on visual review and the source record.

Sources

7 sources reviewed

Further reading

  • 1iX Biopharma via Singapore Exchange The company's own regulatory announcement gives the exact contract figure and date.
  • 4Politico Politico's investigation details the manufacturing-partner licence issue and the extended EUA timeline.
  • 5MedPage Today MedPage Today explains the two-step federal declaration that opened the emergency-use pathway.

The full story

The kernel of truth here is a real government contract. On 12 February 2026, iX Biopharma announced that it had been awarded a US$40.95 million development contract by the United States Government, through the Defense Health Agency Contracting Activity, to fund Wafermine, its sublingual ketamine wafer. The contract is a sole-source Other Transaction Agreement, which is why the clip's 'multi-million-dollar' and 'nearly $41 million' framing is both accurate and slightly loose: the exact figure is $40.95 million.

The product is a thin wafer that dissolves under the tongue, allowing ketamine to be absorbed through the oral mucosa rather than injected. Ketamine is already used in military trauma care and is not an opioid, which is the reason the clip gives for the Pentagon's interest. The 36-month programme is designed to support an FDA Emergency Use Authorization that would allow Department of Defense use before full approval.

The emergency pathway moved in 2026. In July, Defense Secretary Pete Hegseth made a determination about a military emergency, and on 3 September HHS Secretary Robert F. Kennedy Jr. declared that circumstances justified emergency use of drugs identified by the Pentagon for moderate-to-severe acute pain in casualties.

The clip's caveats are also true. The product is not authorised yet, and iX Biopharma has extended its EUA filing timeline. Politico reported in October 2026 that its U.S. manufacturing partner, Orion Specialty Labs in Nevada, had not obtained the required state pharmacy licence. That is why the clip says medics will not be getting boxes of wafers tomorrow.

Kernel of truth

The Pentagon did award a real, multi-million-dollar contract to iX Biopharma for a sublingual ketamine wafer, and the company is genuinely pursuing an FDA Emergency Use Authorization for military use.

Timeline

  1. February 12, 2026

    iX Biopharma announces a US$40.95 million U.S. government development contract for Wafermine, awarded through the Defense Health Agency Contracting Activity. 1iX Biopharma via Singapore Exchange

  2. July 15, 2026

    Defense Secretary Pete Hegseth makes a determination about a military emergency involving risk from certain attacks. 5MedPage Today

  3. September 3, 2026

    HHS Secretary Robert F. Kennedy Jr. declares that circumstances justify emergency use of certain unapproved drugs for troops with moderate-to-severe acute pain. 2Navy Times (Military Times)

  4. October 2026

    Politico reports that U.S. manufacturing partner Orion Specialty Labs lacked a Nevada pharmacy licence and that iX Biopharma extended its EUA filing timeline. 4Politico

How it was framed

Accurate

The post is a branded news explainer whose checkable claims match official filings and independent reporting. It is not a misinformation type; it is an accurate account of a real contract and regulatory process.

  • “Visual proof”. The clip intercuts studio presentation with footage of a robotic pharmaceutical line filling blister packs and a combat medic handling a syringe, illustrating the product and its use.
  • Borrowed authority. The presenter states 'the Defense Department awarded nearly $41 million' and references 'the federal government declared circumstances exist,' anchoring the story in official action.
  • Missing context. The clip does not name the HHS or Defense secretaries or the manufacturing partner, though it does note that questions surround a partner and that the product is still in the pipeline.

The Facebook reel is a repost of a branded Military Times/Defense News vertical explainer. The post title names 'Defense News'; the clip itself directs viewers to militarytimes.com.

Bias

NoneSlightModerateStrong

The clip is a straight news explainer from Military Times: it states the contract and EUA pathway, notes the program is not yet operational, flags the unresolved manufacturing-partner issue, and closes with an open engagement question rather than advocacy.

Bias describes how the post frames its message — the slant of the language, selection and emphasis — and is judged separately from whether the claim is true. A true claim can still be framed with a strong slant.

How we checked

52 s
  1. 1

    We searched for the contract and product using the queries 'Pentagon contract iX Biopharma ketamine wafer $41 million' and 'iX Biopharma Wafermine ketamine wafer Defense Department contract'.

  2. 2

    We compared the clip's claims with iX Biopharma's Singapore Exchange announcement and with reporting from POLITICO Pro, Military Times/Navy Times, MedPage Today, the Washington Times and RTTNews via Nasdaq.

  3. 3

    We reviewed keyframes from the video by eye for consistency of the presenter, set and text overlays.

  4. 4

    We checked whether any existing fact-check covered this item; none does.

✓ Claim checked✓ Media checked✓ Sources checked

Why 92% confidence

High

We rate this HIGH because the central claim is confirmed by the company's own regulatory filing and by at least three independent news outlets, and the clip's caveats are independently confirmed by a separate POLITICO investigation. The media is a branded news explainer with no sign of manipulation, and the claim does not depend on the footage being authentic.

Limits. We did not run an automated synthetic-media detector; our media assessment rests on visual review. We did not independently verify the Nevada licensing status beyond Politico's reporting, and we did not review the full FDA filing, which has not been made.

What we don’t know

  • Whether iX Biopharma will file its Emergency Use Authorization within the 12-month window it has projected.
  • Whether Orion Specialty Labs has since obtained the Nevada pharmacy licence.
  • When, or whether, the FDA will grant an Emergency Use Authorization for military use.

Spot it yourself

Why it looked fake

Looks suspicious, isn’t proof

  • The topic sounds alarming — ketamine for soldiers — and alarm is a reason to check, not evidence of falsity.
  • The clip uses stock footage of a pharmaceutical line and a medic, which can look like generic filler rather than proof.
  • The presenter speaks quickly and uses a dramatic hook ('seconds matter'), which can read as hype.
  • The Facebook repost carries a different outlet name ('Defense News') from the website named in the clip (militarytimes.com), which can look like misattribution.

The actual evidence

  • The company's own Singapore Exchange announcement records the US$40.95 million contract and its date.
  • Independent outlets — POLITICO Pro, Military Times/Navy Times and the Washington Times — report the same figure and recipient.
  • RTTNews via Nasdaq confirms the 36-month programme is designed to support an FDA Emergency Use Authorization.
  • Politico's October 2026 investigation independently confirms the caveat about the Nevada manufacturing partner and the extended EUA timeline.
  1. 1

    Find the primary document

    Search the company name plus 'contract' or 'award' and look for a regulatory filing or press release on an exchange or company site. Here, the SGX announcement gives the exact figure.

  2. 2

    Check whether independent outlets report the same number

    Search the company and product name plus the dollar figure. If several unrelated outlets repeat it, the number is not single-sourced. If only the company says it, treat it as a claim.

  3. 3

    Separate seeking approval from holding approval

    Look for the words 'seeking', 'filing' or 'timeline' versus 'approved' or 'authorised'. A product in the pipeline is not a product in use.

  4. 4

    Inspect the visual details

    Pause on the presenter's face, hands and any on-screen text. Stable features and coherent signage suggest authentic footage; morphing or garbled text is a reason to look closer.

  5. 5

    Check what the clip admits

    A post that volunteers its own caveats — here, the manufacturing-partner questions and the ongoing process — is usually more reliable than one that only asserts.

Takeaway

A story can sound alarming and still be accurate; the way to tell is to find the primary document and see whether independent outlets report the same specifics. Caveats volunteered by the poster are often a sign of care, not weakness.

Questions people ask

Did the Pentagon really award $41 million to iX Biopharma for a ketamine wafer?+

Yes. On 12 February 2026, iX Biopharma announced a US$40.95 million development contract from the U.S. government, awarded through the Defense Health Agency Contracting Activity, for its sublingual ketamine wafer Wafermine. POLITICO Pro and other outlets report the same figure and recipient.

What is Wafermine?+

Wafermine is a thin ketamine wafer that dissolves under the tongue, allowing the drug to be absorbed through the oral mucosa rather than injected. It is being developed for moderate-to-severe acute pain and is described by the company as a non-opioid option for military trauma care.

Has the FDA approved the ketamine wafer for troops?+

No. The product is not authorised. The 36-month contract is designed to support an FDA Emergency Use Authorization that would allow Department of Defense use before full approval, but iX Biopharma has extended its filing timeline and now projects filing within 12 months.

What was the federal emergency declaration about?+

In July 2026, Defense Secretary Pete Hegseth made a determination about a military emergency, and on 3 September 2026 HHS Secretary Robert F. Kennedy Jr. declared that circumstances justified emergency use of certain unapproved drugs for troops with moderate-to-severe acute pain. That opened an EUA route.

Why is ketamine used in military trauma care?+

Ketamine is not an opioid and causes less respiratory depression than morphine or fentanyl. Reporting and a 2023 study describe it as a first-line battlefield analgesic since 2012, with use rising as opioid use for battlefield injuries declined.

Go deeper

Sublingual
Placed under the tongue so a drug is absorbed through the tissue of the mouth rather than swallowed or injected.
Emergency Use Authorization (EUA)
A regulatory pathway that allows unapproved medical products to be used in specific emergencies before full approval.
Other Transaction Agreement
A flexible government contracting vehicle, often used by the Defense Department, that can be awarded without a standard competitive tender.
Sole-source contract
A contract awarded to one company without competing bids, usually because only that company offers the required product or capability.

People also search for

Pentagon ketamine wafer iX BiopharmaWafermine ketamine wafer Pentagon contractDid the Pentagon award $41 million to iX Biopharma?Pentagon wants troops to have ketamine on the battlefieldketamine wafer battlefield medicine military
For educators+
Primary documents versus secondary reportingThe difference between seeking regulatory approval and holding itHow to evaluate branded news explainersCorroboration across independent sources
  • The clip volunteers its own caveats about the manufacturing partner and the ongoing process. How does that affect your trust in the rest of its claims?
  • Why might a viewer assume a video about ketamine for soldiers is fake, and what evidence would change that view?
  • What is the difference between a company's regulatory filing and a news report about it, and why does that difference matter for verification?

About this check

Platform
Facebook
Age when checked
1–2 days old when checked
Where it spread
United States, SG
Audience
US audience
Language
EN
Status
● Post is live
Verified
October 31, 2026, 02:57 UTC
Published
October 31, 2026, 02:57 UTC

Reach. Readers emailed Snopes enough to prompt a check (29 Oct); Google autocomplete leads with 'ketamine wafers for soldiers'

This verdict was generated with AI from the sources shown. AI can make mistakes — check the sources before relying on it.

Check anything yourself, in seconds.

Share any social post or video to What the Fact and get the verdict, the confidence, and the receipts.

Download on theApp StoreGet it onGoogle Play